Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Glycosylation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN1989148A reveals a solid-state synthesis route for 1-alpha-halo-2,2-difluoro-2-deoxy-D-ribofuranose, enabling scalable Gemcitabine production with superior purity.
Patent CN111454270A discloses a novel six-membered ring nucleoside synthesis. Offers improved solubility and scalable routes for antiviral API manufacturing.
Novel Ni(II)-catalyzed method for high stereoselectivity 1,2-cis-glycosides. Reduces steps, improves yield, offers cost-effective API intermediate manufacturing.
Patent CN114163483A discloses a novel PTFAI-mediated alpha-glycosylation method offering high stereoselectivity and mild conditions for reliable pharmaceutical intermediate supply.
Patent CN109111490B introduces a novel halogenated pivaloyl glucopyranose route for SGLT2 inhibitors, offering superior stereoselectivity and industrial scalability for pharmaceutical manufacturing.
Patent CN110642897A reveals a novel, scalable synthesis for beta-nicotinamide riboside chloride. High-purity NRC precursor for NMN manufacturing without chromatography.
Patent CN102127135A reveals a mild, gold-catalyzed glycosylation method for pyrimidine and purine nucleosides, offering significant cost reduction in API manufacturing.
Patent CN111662260B reveals a 7-step synthesis of saffloneoside. Offers stable intermediates and scalable routes for cerebral ischemia drug development.
Patent CN101747390B details a high-yield route for edaravone glucuronide, offering significant cost reduction in API manufacturing and improved purity.
Novel synthesis route for 3-O-propargyl nucleoside avoids isomers ensuring high purity and scalable manufacturing for pharmaceutical intermediates globally.
Advanced chemical synthesis of Plesiomonas shigelloides O51 antigen oligosaccharides ensures high purity and scalable supply for next-generation vaccine intermediates.
Patent CN111018928A reveals a novel 2-step synthesis for high-purity gastrodin hemihydrate, offering significant cost reduction and scalable manufacturing for global supply chains.
Patent CN102942601A reveals a streamlined route for Fondaparinux sodium intermediates, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Novel catalytic glycosylation for Doxifluridine reduces Lewis acid usage and improves yield to 98%. A reliable API intermediate supplier for cost reduction.
Patent CN111233949A details a novel one-pot three-enzyme method for GM3 synthesis, offering high stereoselectivity and cost reduction for pharmaceutical intermediate manufacturing.
Patent CN119654332A reveals a stereoselective route for DNMT1 inhibitor intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN112159447B details a novel DMAP-catalyzed route for 2-chloroadenosine, offering superior purity and yield while eliminating heavy metal contamination for scalable API production.
Novel three-step synthesis patent CN103694287A offers enhanced yield and purity. Reliable supply chain for pharmaceutical intermediates with significant cost reduction potential.
Patent CN112480197B reveals a cost-effective route for cytosine nucleoside using cyanoacetaldehyde urea acetal, offering significant supply chain advantages.
Patent CN101497639B details a scalable Decitabine synthesis using toluoyl protection and fractional crystallization, offering significant cost reduction in pharmaceutical manufacturing.